

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/5785AE24A58EN.html>

Date: March 2018

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: 5785AE24A58EN

Abstracts

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H1 2018

SUMMARY

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 6 - Pipeline Review, H1 2018, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner.

Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 11 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Metabolic Disorders which include indications Schizophrenia, Alzheimer's Disease, Psychiatric Disorders, Anxiety Disorders, Cognitive Disorders, Mild Cognitive Impairment, Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (Manic Depression), Dementia, Dementia Associated With Alzheimer's Disease, Depression, Major Depressive Disorder, Neurology, Obesity, Parkinson's Disease, Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder and Tourette Syndrome.

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)

The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their

major and minor projects

The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Overview

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies

Involved in Therapeutics Development

Acorda Therapeutics Inc

Adamed Sp z oo

Avineuro Pharmaceuticals Inc

Celon Pharma SA

H. Lundbeck AS

Reviva Pharmaceuticals Inc

Suven Life Sciences Ltd

Teva Pharmaceutical Industries Ltd

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug

Profiles

ADN-1184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-2013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-3662 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-3208 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-3205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-322 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-492 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landipirdine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-35700 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Antagonize 5-HT₆ Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-512 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) -
Discontinued Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Product
Development Milestones

Featured News & Press Releases

Nov 13, 2017: Suven Life sciences announces presentation on its cognitive disorders
drug candidate SUVN-502 at Neuroscience 2017 at Washington DC

Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND
Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension

Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for
Pulmonary Arterial Hypertension (PAH)

May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results
for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016

Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients
with treatment resistant schizophrenia

Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer's
Disease

Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for
Memory Deficits

Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective
5-HT6 Receptor Antagonist

Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease
Dementia And Provides Outlook Update For Near Term Pipeline Events

Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV
NS5A Inhibitor

Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's
Disease

Jul 30, 2014: Biotie updates outlook on SYN120

Jul 16, 2014: Biotie Therapies Selects Bracket's CDR System for Phase 2 Trial of
Treatment of Parkinson's Disease

Jul 08, 2014: Biotie awarded USD 2 million grant from The Michael J. Fox Foundation
for a clinical study with SYN120 in Parkinson's Disease Dementia

Nov 05, 2013: Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting
with FDA for RP5063

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Acorda Therapeutics Inc, H1 2018
Pipeline by Adamed Sp z oo, H1 2018
Pipeline by Avineuro Pharmaceuticals Inc, H1 2018
Pipeline by Celon Pharma SA, H1 2018
Pipeline by H. Lundbeck AS, H1 2018
Pipeline by Reviva Pharmaceuticals Inc, H1 2018
Pipeline by Suven Life Sciences Ltd, H1 2018
Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administrations, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Acorda Therapeutics Inc

Adamed Sp z oo

Avineuro Pharmaceuticals Inc

Celon Pharma SA

H. Lundbeck AS

Reviva Pharmaceuticals Inc

Suven Life Sciences Ltd

Teva Pharmaceutical Industries Ltd

I would like to order

Product name: 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/5785AE24A58EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/5785AE24A58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

